The herpesvirus accessory protein γ134.5 facilitates viral replication by disabling mitochondrial translocation of RIG-I.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
03 2021
Historique:
received: 06 08 2020
accepted: 02 03 2021
entrez: 26 3 2021
pubmed: 27 3 2021
medline: 24 7 2021
Statut: epublish

Résumé

RIG-I and MDA5 are cytoplasmic RNA sensors that mediate cell intrinsic immunity against viral pathogens. While it has been well-established that RIG-I and MDA5 recognize RNA viruses, their interactive network with DNA viruses, including herpes simplex virus 1 (HSV-1), remains less clear. Using a combination of RNA-deep sequencing and genetic studies, we show that the γ134.5 gene product, a virus-encoded virulence factor, enables HSV growth by neutralization of RIG-I dependent restriction. When expressed in mammalian cells, HSV-1 γ134.5 targets RIG-I, which cripples cytosolic RNA sensing and subsequently suppresses antiviral gene expression. Rather than inhibition of RIG-I K63-linked ubiquitination, the γ134.5 protein precludes the assembly of RIG-I and cellular chaperone 14-3-3ε into an active complex for mitochondrial translocation. The γ134.5-mediated inhibition of RIG-I-14-3-3ε binding abrogates the access of RIG-I to mitochondrial antiviral-signaling protein (MAVS) and activation of interferon regulatory factor 3. As such, unlike wild type virus HSV-1, a recombinant HSV-1 in which γ134.5 is deleted elicits efficient cytokine induction and replicates poorly, while genetic ablation of RIG-I expression, but not of MDA5 expression, rescues viral growth. Collectively, these findings suggest that viral suppression of cytosolic RNA sensing is a key determinant in the evolutionary arms race of a large DNA virus and its host.

Identifiants

pubmed: 33770145
doi: 10.1371/journal.ppat.1009446
pii: PPATHOGENS-D-20-01727
pmc: PMC7996975
doi:

Substances chimiques

Receptors, Immunologic 0
Viral Proteins 0
RIGI protein, human EC 3.6.1.-
DEAD Box Protein 58 EC 3.6.4.13

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009446

Subventions

Organisme : NIAID NIH HHS
ID : R37 AI087846
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI145359
Pays : United States
Organisme : NIH HHS
ID : P51 OD010425
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI148148
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI146409
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127774
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI087846
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI145296
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI104002
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Front Immunol. 2017 Jan 03;7:662
pubmed: 28096803
PLoS One. 2017 Aug 14;12(8):e0182961
pubmed: 28806404
J Virol. 2001 Jun;75(11):5189-96
pubmed: 11333900
Oncogene. 2008 Jul 10;27(30):4150-60
pubmed: 18362887
J Biol Chem. 2009 Jan 9;284(2):1097-105
pubmed: 19010780
Science. 1990 Nov 30;250(4985):1262-6
pubmed: 2173860
J Virol. 2018 Sep 26;92(20):
pubmed: 30045990
J Gen Virol. 1993 Nov;74 ( Pt 11):2493-7
pubmed: 8245868
J Virol. 2000 Sep;74(17):7989-96
pubmed: 10933707
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3266-70
pubmed: 1314384
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
J Virol. 2013 Jul;87(13):7301-8
pubmed: 23596298
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
PLoS Pathog. 2016 Oct 25;12(10):e1005966
pubmed: 27780231
Nature. 2007 Apr 19;446(7138):916-920
pubmed: 17392790
Clin Cancer Res. 2017 Jul 15;23(14):3566-3574
pubmed: 28495911
Immunity. 2008 Oct 17;29(4):538-50
pubmed: 18818105
Nat Immunol. 2010 Nov;11(11):997-1004
pubmed: 20890285
Genes Immun. 2015 Dec;16(8):552-66
pubmed: 26513235
J Virol. 2012 Apr;86(7):3528-40
pubmed: 22301138
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
J Virol. 2003 Mar;77(6):3409-17
pubmed: 12610116
Cell Host Microbe. 2015 Apr 8;17(4):478-88
pubmed: 25816774
Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):582-7
pubmed: 17190814
J Virol. 2016 Sep 29;90(20):9406-19
pubmed: 27512060
J Virol. 2003 Oct;77(20):10917-28
pubmed: 14512542
J Virol. 2007 Nov;81(22):12128-34
pubmed: 17855538
J Virol. 2019 Nov 13;93(23):
pubmed: 31511389
PLoS Pathog. 2013;9(8):e1003533
pubmed: 23950712
J Virol. 2016 Oct 28;90(22):10414-10422
pubmed: 27630226
Trends Immunol. 2019 Dec;40(12):1134-1148
pubmed: 31735513
Annu Rev Immunol. 2018 Apr 26;36:667-694
pubmed: 29677479
Nat Immunol. 2016 May;17(5):523-30
pubmed: 26998762
J Virol. 2009 Dec;83(23):12626-30
pubmed: 19759130
J Virol. 2012 Feb;86(4):2188-96
pubmed: 22171259
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Cell Host Microbe. 2009 May 8;5(5):439-49
pubmed: 19454348
Nat Immunol. 2011 Sep 04;12(10):959-65
pubmed: 21892174
PLoS Pathog. 2018 Jan 22;14(1):e1006852
pubmed: 29357390
J Gen Virol. 1989 Nov;70 ( Pt 11):3073-8
pubmed: 2555437
Cell Host Microbe. 2019 Oct 9;26(4):493-503.e6
pubmed: 31600501
J Virol. 2013 Dec;87(24):13141-9
pubmed: 24067967
J Exp Med. 2012 Aug 27;209(9):1567-82
pubmed: 22851595
J Virol. 1990 Mar;64(3):1014-20
pubmed: 2154589
Mol Ther Oncolytics. 2017 Mar 01;5:1-10
pubmed: 28345027
Immunity. 2013 Mar 21;38(3):437-49
pubmed: 23499489
J Gen Virol. 1994 Dec;75 ( Pt 12):3679-86
pubmed: 7996163
Cell Host Microbe. 2012 May 17;11(5):528-37
pubmed: 22607805
Nat Commun. 2018 Nov 19;9(1):4841
pubmed: 30451863
J Virol. 2019 Aug 13;93(17):
pubmed: 31189704
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Lancet. 2001 May 12;357(9267):1513-8
pubmed: 11377626
Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10516-20
pubmed: 7479831
Cell Host Microbe. 2007 Mar 15;1(1):23-35
pubmed: 18005679
J Virol. 2003 Jan;77(1):228-36
pubmed: 12477828
J Virol. 2014 May;88(10):5778-87
pubmed: 24623417
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Nat Immunol. 2018 Jan;19(1):53-62
pubmed: 29180807
Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):843-8
pubmed: 9023344
mBio. 2018 Jul 3;9(4):
pubmed: 29970461
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Immunol. 2004 Jul;5(7):730-7
pubmed: 15208624
J Gen Virol. 2009 Jan;90(Pt 1):74-8
pubmed: 19088275
J Virol. 2011 Oct;85(20):10899-904
pubmed: 21835791
Cell Host Microbe. 2016 Nov 9;20(5):674-681
pubmed: 27746097
PLoS Pathog. 2017 Oct 30;13(10):e1006677
pubmed: 29084250
J Biol Chem. 2014 Dec 26;289(52):35795-805
pubmed: 25355318
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
Virology. 2009 Sep 1;391(2):171-6
pubmed: 19628239
Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17717-22
pubmed: 16301520
J Virol. 2002 Sep;76(18):9434-45
pubmed: 12186925
EMBO J. 2006 Sep 20;25(18):4207-14
pubmed: 16946700
J Gen Virol. 1968 May;2(3):357-64
pubmed: 4300104
Nat Immunol. 2009 Oct;10(10):1065-72
pubmed: 19609254
J Virol. 2004 Jul;78(14):7653-66
pubmed: 15220440
mBio. 2017 Jul 5;8(4):
pubmed: 28679751
Nature. 2008 Oct 2;455(7213):674-8
pubmed: 18724357
J Exp Med. 2015 Aug 24;212(9):1371-9
pubmed: 26216125
PLoS Pathog. 2019 Feb 11;15(2):e1007582
pubmed: 30742689
Cell Host Microbe. 2016 Dec 14;20(6):770-784
pubmed: 27866900
Cell Host Microbe. 2010 Dec 16;8(6):496-509
pubmed: 21147464
Science. 2007 Sep 14;317(5844):1522-7
pubmed: 17872438
Cell. 2009 Aug 7;138(3):576-91
pubmed: 19631370
Nature. 2005 Oct 20;437(7062):1167-72
pubmed: 16177806
J Biochem. 2012 Jan;151(1):5-11
pubmed: 21890623
Immunotherapy. 2019 Jun;11(8):705-723
pubmed: 31045464
J Virol. 1986 Feb;57(2):629-37
pubmed: 3003394
J Virol. 2008 Jan;82(2):609-16
pubmed: 17977974
Nat Rev Immunol. 2020 Sep;20(9):537-551
pubmed: 32203325

Auteurs

Xing Liu (X)

Department of Microbiology and Immunology University of Illinois College of Medicine, Chicago, Illinois, United States of America.

Yijie Ma (Y)

Department of Microbiology and Immunology University of Illinois College of Medicine, Chicago, Illinois, United States of America.

Kathleen Voss (K)

Center for Innate Immunity and Immune Disease, Department Immunology, University of Washington, Seattle, Washington, United States of America.

Michiel van Gent (M)

Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, Florida, United States of America.
Department of Microbiology, The University of Chicago, Illinois, United States of America.

Ying Kai Chan (YK)

Department of Genetics, Harvard Medical School, Boston, Massachusetts, United States of America.
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, United States of America.

Michaela U Gack (MU)

Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, Florida, United States of America.
Department of Microbiology, The University of Chicago, Illinois, United States of America.

Michael Gale (M)

Center for Innate Immunity and Immune Disease, Department Immunology, University of Washington, Seattle, Washington, United States of America.

Bin He (B)

Department of Microbiology and Immunology University of Illinois College of Medicine, Chicago, Illinois, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH